News
For three consecutive years, Wanbande Pharmaceutical Group has been recognized among the Top 500 High-Tech Enterprises in Zhejiang Province for Innovation Capability!
Date:
30 Dec,2024
Introduction: Recently, the official list of the "Top 500 Zhejiang Provincial High-Tech Enterprises by Innovation Capability" for 2024 was unveiled. The ranking was compiled by the Zhejiang Provincial High-Tech Enterprise Association, which commissioned the Zhejiang Provincial Institute of Science and Technology Information to conduct an evaluation of innovation capabilities among high-tech enterprises. Through a comprehensive comparison of multiple key indicators, the top 500 Zhejiang-based high-tech companies in terms of innovation strength were identified for 2024. Building on this, the top 100 enterprises were further selected based on individual metrics such as main business revenue, R&D expenditure, total profit and tax, and new product output. Additionally, the top 100 companies were chosen separately within the digital economy, life sciences & health, and new materials sectors, while another set of top 100 was identified specifically for the service industry.
Wanbangde Pharmaceutical Group Co., Ltd. has been listed among "Top 500 Zhejiang Provincial High-Tech Enterprises by Innovation Capability in 2024" "The list reveals that this is the third consecutive year the company has proudly made the cut. Meanwhile, the company..." Selected as one of the "Top 100 in the Life and Health Hub" , fully demonstrating the company's robust capability in technological innovation.
Key Metrics of the 2023 Top 500 Companies
● Achieved operating revenue of 2,338.25 billion yuan, accounting for 32.9% of the total high-tech enterprises;
● Achieved profits and taxes totaling 483.65 billion yuan, accounting for 57.9% of the total high-tech enterprises;
● R&D expenditures totaled 161.55 billion yuan, accounting for 37.5% of the total investment by high-tech enterprises.
Top 500 companies demonstrate outstanding innovation capabilities.
● High R&D investment intensity among the Top 500 leads the way for high-tech enterprises;
● R&D investment among the Top 500 companies follows the classic 80/20 rule;
● The Top 500 companies prioritize talent, especially in building a strong pool of research personnel;
● The Top 500 companies place great emphasis on intellectual property and research achievements.
High-tech enterprises are at the forefront of scientific and technological innovation, serving as the main driving force behind innovative development in manufacturing. Over the years, Wanbande Pharmaceutical has consistently prioritized technological innovation as the primary engine propelling its growth, leveraging multiple cutting-edge platforms—including the provincial-level Key Academician Workstation, the Provincial Postdoctoral Workstation, the Provincial Enterprise Research Institute, and the Provincial Technology Center—to provide robust talent support for pharmaceutical R&D.
In terms of product innovation, Wanbangde Pharmaceutical adheres to the "patient-centric" philosophy, deeply understanding patient needs and market trends while continuously driving forward groundbreaking advancements. By combining independent R&D with innovative collaboration, the company has enriched its pipeline, establishing a comprehensive R&D ecosystem where innovative drug development, generic drug research, API development, and traditional Chinese medicine innovation thrive in tandem. Notably, the company’s innovative drug initiatives are focused on four key therapeutic areas: (major) neurological disorders, metabolic conditions, autoimmune diseases, and rare diseases—leveraging years of accumulated expertise to deliver clinically essential, cutting-edge therapies that address unmet patient needs.
This prestigious recognition is a powerful testament to Wanbangde Pharmaceutical's steadfast commitment to innovation and sustainable development over the years. Moving forward, Wanbangde Pharmaceutical will continue to embrace an innovative spirit, strengthening its innovation framework, nurturing a thriving innovation ecosystem, and enhancing its capacity for groundbreaking advancements. Together, we aim to achieve even greater success on the path of science and technology, ultimately contributing to the health and well-being of people around the globe.
Related Recommendations